On August 16, China National Food and Drug Administration (SFDA) announced that Zhejiang Hisun Pharmaceutical Co., LTD. (hereinafter referred to as "Hisun Pharmaceutical") valsartan tablets were approved successfully.
The clinical study of this variety was completed by Duzheng Biology "One-stop" (changsha Central Hospital, a cooperative co-construction unit, was responsible for the clinical study, Serong Intelligence was responsible for recruitment, Leading Medicine was responsible for SMO service, weights and data management and statistical analysis). The verification, clinical and analytical tests were exempted.
Since the establishment of the company in 2016, Hisun pharmaceutical and Duzheng Biological signed the first clinical research project cooperation agreement. In the past five years, the two sides have worked closely and entrusted Duzheng Biological to carry out a number of "one-stop" clinical studies, which has helped 4 drugs to be approved successfully.
We look forward to continued cooperation between the two sides in the future to ensure drug safety and effectiveness through high-quality research and accelerate the approval of more high-quality new drugs and generic drugs.